Regeneron Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Regeneron reported quarterly adjusted earnings of $20.07 per share, beating the $16.24 average estimate from twenty-four analysts. Revenue rose 36.3% to $5.12 billion, above the expected $4.54 billion. Reported earnings per share were $18.45 and net income was $1.95 billion.

Confirmed

Global impact / market context

Higher revenue and profit per share mean Regeneron kept more money from each sale and beat what analysts expected. That can support the shares because the average analyst rating is buy and the median price target of $865 sits about 5.3% above the last close of $818.77.

Analyst inference

Analysts had raised the mean earnings estimate by about 5.8% over three months, yet four analysts cut estimates in the last 30 days, which means recent views were mixed. Shares had risen 8.0% this quarter and 6.1% this year, so results arrived after a positive run.

Analyst inference

What to watch

1. The median 12-month price target is $865.00, about 5.3% above the last closing price of $818.77, which means analysts on average see limited further upside from that close. Confirmed
2. Watch whether the four analysts who cut estimates in the last 30 days revise again now that results beat expectations, since estimate changes could shift the average rating and price target. Proposed
3. Watch whether the 36.3% revenue rise repeats next quarter; if growth slows, the buy ratings and price target may come under pressure and change how investors position in the stock. Analyst inference

Evidence

• Original source link unavailable